Development of a sustained release dosage form for alpha-lipoic acid. I. Design and in vitro evaluation.
The purpose of this study was the design and evaluation of a sustained release dosage form for the oral administration of alpha-lipoic acid. The cationic polymer chitosan was used in order to provide a controlled drug release based on ionic interactions with the anionic drug. The effect of such ionic interactions on the release of alpha-lipoic acid could be verified by diffusion studies. In vitro release studies with tablets (diameter: 10.0 mm; thickness: approximately 4 mm) containing 80% alpha-lipoic acid and 20% chitosan acetate showed a controlled drug release over a time period of 24 h. Raising the ratio of chitosan acetate in such delivery systems led to an even stronger retardation of drug release. In addition, permeation studies carried out in Ussing-type chambers with freshly excised intestinal mucosa from guinea pigs demonstrated no significant (p < 0.05) influence of the degree of drug ionization on its absorption behavior. The apparent permeability coefficient (Papp) for alpha-lipoic acid was determined to be 1.39 +/- 0.28 x 10(-5) cm/sec at pH 6.4 (means +/- SD). The use of a sustained delivery system for alpha-lipoic acid, which is based on ionic interactions, should therefore have no influence on the absorption behavior of the drug. The sustained release dosage forms described here might provide a constant plasma level of the drug being highly beneficial for various therapeutic reasons.
Bernkop-Schnürch
Andreas
A
Institute of Pharmacy, Department of Pharmaceutical Technology, Leopold-Franzens-University Innsbruck, Innsbruck, Austria. andreas.bernkop@uibk.ac.at
Schuhbauer
Hans
H
Clausen
Andreas E
AE
Hanel
Roland
R
D000465:Algorithms; D000975:Antioxidants / Q000008:administration & dosage*; D002686:Chitin / Q000031:analogs & derivatives*; D048271:Chitosan; D003692:Delayed-Action Preparations; D004058:Diffusion; D004337:Drug Carriers; D015195:Drug Design; D004553:Electric Conductivity; D010539:Permeability; D013607:Tablets; D008063:Thioctic Acid / Q000008:administration & dosage*
D000975:Antioxidants; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D013607:Tablets; D002686:Chitin; D008063:Thioctic Acid; D048271:Chitosan